Overview

CD8 PET Imaging in Metastatic Solid Tumours

Status:
RECRUITING

Trial end date:
2028-11-01

Target enrollment:

Participant gender:

Summary

This is a multi-center, single-arm trial designed to evaluate the safety and imaging characteristics of 89Zr-Df-crefmirlimab in patients with locally advanced or metastatic solid tumours prior to and during PD-1 antibody therapy.

Phase:

PHASE2

Details

Lead Sponsor:

University Medical Center Groningen

Treatments:

Nivolumab